---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-021095"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T13:55:31.145370+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# MannKind FY 2023 revenue doubled to $199M; Q4 posts GAAP net income of $1M

## Summary
- FY 2023 total revenues $199M, +99% YoY; Q4 revenues $58M, +62% YoY.
- Q4 2023 net income of $1M (GAAP); Non-GAAP net income of $7M.
- Afrezza Q4 net revenue $15.5M (+29%); Tyvaso DPI royalties Q4 $21.0M (+132%).
- Cash $302.3M at year-end; plans Phase 3 for MNKD-101 and Phase 1 for MNKD-201 in H1 2024.
- Commercial product gross margin 70% in Q4 vs 77% prior year; lower due to cost timing.

## SEC filing metadata
- accession: 0000950170-24-021095
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000095017024021095/0000950170-24-021095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000095017024021095/mnkd-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-021095
- JSON: https://secwatch.observer/filing/0000950170-24-021095.json
- Plain text: https://secwatch.observer/filing/0000950170-24-021095.txt

## Key facts
- Earnings Releases
  MANNKIND CORP reported the quarter and full year ended December 31, 2023 results: revenue Total revenues of $199M, net income 4Q 2023 Net income of $1M.
  - Period: the quarter and full year ended December 31, 2023
  - Revenue: Total revenues of $199M
  - Net income: 4Q 2023 Net income of $1M
  - Result: reported results
  source text: REPORTS 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS: PROVIDES CLINICAL DEVELOPMENT UPDATE Conference Call to Begin Today at 5:00 p.m. (ET) • 2023 Total revenues of $199M; +99% vs. 2022 • 4Q 2023 Total revenues of $58M; +62% vs. 2022 • 4Q 2023 Net income of $1M; Non-GAAP net income of $7M • $302M of cash and cash equivalents and investments at
  evidence_url: https://www.sec.gov/Archives/edgar/data/899460/000095017024021095/0000950170-24-021095-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.